Tabellen nedenfor viser de bivirkninger, der forekom hyppigere (p ≤ 0, 05) for telmisartan plus hydrochlorthiazid end for placebo i de kliniske forsøg.
Adverse reactions reported in all clinical trials and occurring more frequently (p ≤ 0.05) with telmisartan plus hydrochlorothiazide than with placebo are shown below according to system organ class.